HMO's BACKSTORY 

A BRIEF HISTORY OF HUMAN MILK OLIGOSACCHARIDE

The discovery of these non-digestible sugars (HMOs), which make up 10 percent of the dry weight of human milk, went through a metamorphosis of sorts over the decades as studies built upon each other like scaffolding, in one fascinating discovery after another.

Interest in milk sugars started more than 100 years ago with the eventual discovery of HMOs driven by both scientists and physicians, each with different perspectives and interests.

Pediatricians and microbiologists were trying to understand the observed health benefits associated with human milk feeding. Chemists were trying to characterize the carbohydrates uniquely found in human milk.

A KEY CLUE IS UNEARTHED 

A BRIEF HISTORY OF HUMAN MILK OLIGOSACCHARIDE

By the end of the 19th century: mortality rates were as high as 20-30% in the first year of an infant’s life.

Imagine that.

Only seven out of every 10 babies were living to age four. The stress. The heartache. The tragedy. But it was observed that breast-fed infants had a much higher chance of survival and had lower incidences of diarrhea and other diseases than “bottle-fed” infants.

This marked a crucial discovery. The mortality rate was seven times higher among bottle-fed infants compared with breast-fed infants. A major breakthrough for infant survival was the discovery of microorganisms and their importance to health, and the observation that non-digestible milk carbohydrates (later named human milk oligosaccharides) play an important role in the growth of these microorganisms.

HUMAN MILK vs. COW'S MILK 

A BRIEF HISTORY OF HUMAN MILK OLIGOSACCHARIDE

In parallel to the observations by pediatricians and microbiologists, chemists also showed great interest after Eschbach found human milk contained a different type of sugar than cow’s milk.

They found that the lactose in human and bovine milk was identical, except that human milk contained another type of carbohydrate. In the early 1930s, researchers were able to characterize this unique carbohydrate fraction and named it “gynolactose”. A few years later, Michel Polonowski and Jean Montreuil separated the first 2’- fucosyllactoses (2′-fucosyllactose and 3-fucosyllactose) from “gynolactose”. This marked the discovery of the first individual HMO. In the following years, Montreuil's group in France and Kuhn's group in Germany discovered more than a dozen individual human milk oligosaccharides.

HMOs are made up of a combination of five simple sugar “building blocks”:

● Glucose (Glc)
● Galactose (Gal)
● N-acetylglucosamine (GlcNAc)
● Fucose (Fuc)
● Sialic acid (Sia)

By now, hundreds of different HMOs have been identified, but not every mother synthesizes the same set of oligosaccharides. Oligosaccharide amount and composition vary between women and over the course of lactation. Milk from randomly selected mothers contain as few as 23 and as many as 130 different oligosaccharides. To date, more than 200 non-digestible and non-nutritional carbohydrates have been identified from human milk.   

NEW USES FOR HMO EMERGE 

A BRIEF HISTORY OF HUMAN MILK OLIGOSACCHARIDE

As the research continued, scientists determined the HMOs, particularly the one dubbed 2’-FL, could aid babies in the battle against infectious diseases, in addition to helping them fight viruses of the gut, respiratory tract, and urinary tract. Scientists also determined 2'-FL could aid in the immune system over the long term.

Moreover, further studies established that an abnormal gut microbiota contributed to diabetes pathology. Low levels of bifidobacteria have been reported in diabetics, in addition to obese individuals, as well as those taking antibiotics and people dealing with bowel issues.

With the vast amount of information emerging from studies, the importance of HMOs was hard to ignore. Just within the last five years, methods for utilizing HMOs began to surface, both as an ingredient in baby formula and as a supplement for adults.

Studies indicated that HMOs, 2’-FL and LNnT, were safe for healthy adults and could create stability within the gut microbiota. Today, the benefits to adults are equal to those for infants - aiding in the fight against irritable bowel syndrome, allergies, and the aging brain, according to data cited in a 2019 Bloomberg report. 

REFERENCES

1. Montreuil, J. "The saga of human milk gynolactose." New Perspectives in Infant Nutrition, Sawaztki, G., Renner, B., Eds., Georg Thieme Verlag, Stuttgart (1993): 1-11.

2. Kunz, Clemens. "Historical aspects of human milk oligosaccharides." Advances in Nutrition 3.3 (2012): 430S-439S.

3. German, J. Bruce, et al. "Human milk oligosaccharides: evolution, structures and bioselectivity as substrates for intestinal bacteria." Personalized nutrition for the diverse needs of infants and children. Vol. 62. Karger Publishers, 2008. 205-222.

4. Bode, Lars. "Human milk oligosaccharides: every baby needs a sugar mama." Glycobiology 22.9 (2012): 1147-1162.

5. German, J. Bruce, et al. "Human milk oligosaccharides: evolution, structures and bioselectivity as substrates for intestinal bacteria." Personalized nutrition for the diverse needs of infants and children. Vol. 62. Karger Publishers, 2008. 205-222.

6. Moukarzel, Sara, and Lars Bode. "Human milk oligosaccharides and the preterm infant: a journey in sickness and in health." Clinics in Perinatology 44.1 (2017): 193-207.

7. Smilowitz, Jennifer T., et al. "Breast milk oligosaccharides: structure-function relationships in the neonate." Annual review of nutrition 34 (2014): 143-169.

8. Pediatr Gastroenterol Hepatol Nutr. 2019 Jul; 22(4): 330–340. Published online 2019 Jun 25. doi: 10.5223/pghn.2019.22.4.330

9. Lianghui Cheng, Renate Akkerman, Chunli Kong, Marthe T. C. Walvoort & Paul de Vos (2020) More than sugar in the milk: human milk oligosaccharides as essential bioactive molecules in breast milk and current insight in beneficial effects, Critical Reviews in Food Science and Nutrition, DOI:

10. 1080/10408398.2020.1754756 10. Vandenplas, Y.; Berger, B.; Carnielli, V.P.; Ksiazyk, J.; Lagström, H.; Sanchez Luna, M.; Migacheva, N.; Mosselmans, J.-M.; Picaud, J.-C.; Possner, M.; Singhal, A.; Wabitsch, M. Human Milk Oligosaccharides: 2′-Fucosyllactose (2′-FL) and Lacto-N-Neotetraose (LNnT) in Infant Formula. Nutrients 2018, 10, 1161.

EXPLAINING HMO

YOUR GUIDE TO HUMAN MILK OLIGOSACCHARIDE

  • 1. WHAT IS HMO?
  • 2. HISTORY OF HMO?
  • 3. HOW IS HMO MADE?
  • 4. IMPACT ON GUT HEALTH
  • 5. IMPACT ON IMMUNE SYSTEM
  • 6. HMO vs. OTHER PREBIOTICS
  • 7. PureHMO® LINE

INTERESTED IN LEARNING MORE ABOUT HMO? 

THE LATEST NEWS, RESEARCH AND EXCLUSIVE INFO SENT STRAIGHT TO YOUR INBOX

The cookie settings on this website are set to 'allow all cookies' to give you the very best experience. Please click Accept Cookies to continue to use the site.
You have successfully subscribed! Please use code "15LayerOrigin" at checkout to redeem your discount
This email has been registered